CSL Limited is a biopharmaceutical company engaged in the research, development, manufacture, marketing and distribution of biopharmaceutical and allied products. It operates in three segments: CSL Behring, which is engaged in manufacturing, marketing and developing plasma products; Intellectual Property Licensing, which is engaged in licensing to unrelated third parties of intellectual property generated by the Company, and Other Human Health, which comprises CSL Bioplasma and CSL Biotherapies. These businesses manufacture and distribute biotherapeutic products. It operates in Australia, United States, Switzerland and Germany.

DFB Pharmaceuticals makes products that protect its armor -- the skin. Through its Healthpoint subsidiary, the pharmaceutical holding company develops, acquires, and markets drug brands that prevent or treat disorders associated with skin and soft tissue. Its portfolio of more than 50 prescription and over-the-counter (OTC) products includes dermatology creams, surgical scrubbing solutions, and wound cleansers and dressings. Its DPT Laboratories subsidiary offers contract manufacturing of semi-solid and liquid drugs, while Phyton Biotech produces active pharmaceutical ingredients (APIs) for DFB and other drug makers in the area of plant-cell culture technology.

Alizyme is fighting the good fight against ills brought on by the good life. The development-stage biotechnology company licenses drug candidates and develops them. It targets conditions prevalent primarily in industrialized countries, including obesity, type 2 diabetes (often associated with obesity), and ulcerative colitis. Alizyme is focused on developing a family of lipase inhibitors, which prevent the body from absorbing fat. In addition to its pipeline of treatments for lifestyle-related conditions, the company is developing a drug for mucositis, cancer therapy-induced damage to the gastrointestinal tract.

Interleukin Genetics, Inc. was founded in 1986 and is headquartered in Waltham, Massachusetts. Interleukin Genetics, Inc., together with its subsidiaries, focuses on developing, acquiring, and commercializing personalized health products that help individuals improve and maintain their health through preventive measures in the United States and internationally. It conducts, researches, develops, markets, and sells genetic test panels primarily in inflammatory and metabolic areas to provide insight into health, wellness, and disease. The company markets and distributes genetic tests under the GENSONA brand, through a strategic partnership with Alticor; and PST tests through sales and marketing partners to dentists and periodontists. It offers genetic tests for periodontal disease risk assessment, cardiovascular risk assessment, and general nutrition assessment. The company has research collaborations with the University of Sheffield, Tufts University, New York University, Harvard University, the Mayo Clinic, California Pacific Medical Center, Boston University, the University of Arkansas, Tongji Medical College, University of North Carolina, and Yonsei University.

Dyadic International, Inc. (Dyadic) is an early-stage biotechnology company. The Company has operations in the United States, the Netherlands and Poland. Dyadic uses its technologies to conduct research and development (R&D) and commercial activities for the discovery, development, manufacture and sale of products and solutions for the bioenergy, industrial enzyme, and biopharmaceutical industries. The Company derives all of its revenues from the licensing of its technologies and the sale of its enzymes. The Company is a holding company that holds all of Dyadic International (USA), Inc. (Dyadic-Florida). Dyadic-Florida owns all of Geneva Investment Holdings Limited, Dyadic Nederland BV, and Dyadic International Sp. z o.o. Dyadic’s R&D activities focus on its fungal strains and associated technologies. In particular, Dyadic uses its Trichoderma and C1 fungal strains in the production of its industrial enzymes.

Chesapeake Biological Laboratories (CBL) provides product development and commercial drug production services for pharmaceutical and biotechnology companies. It also manufactures experimental drugs for use in clinical trials. The company specializes in biopharmaceuticals, materials derived from naturally occurring biological substances. CBL's primary operations are sterilizing and filling liquid drugs and production lyophilization, the process of filling drug containers while limiting the product's exposure to room temperature. CBL is a wholly-owned subsidiary of Canadian biopharma firm Cangene.

Zila, Inc., a diagnostic company, engages in the prevention, detection, and treatment of oral cancer and periodontal disease. It manufactures and markets ViziLite Plus with TBlue, its flagship product, for early detection of oral abnormalities that could lead to cancer. In addition, the company designs, manufactures, and markets a suite of proprietary products directly to dental professionals for periodontal disease, including the Rotadent Professional Powered Brush, the Pro-Select Platinum ultrasonic scaler, and a portfolio of oral pharmaceutical products for in-office and home-care use. Further, it had certain technology rights, and the United States and foreign patent rights related to the OraTest, an oral cancer diagnostic product. Zila, Inc. markets and sells its products in the United States and Canada through direct sales force, and internationally through third party distributors. The company was founded in 1980 and is headquartered in Phoenix, Arizona. As of September 18, 2009, Zila, Inc. operates as a subsidiary of Tolmar, Inc.

Pharmaxis has an ax to grind with chronic respiratory and autoimmune diseases. The Australian company researches, develops, and markets therapeutic pharmaceutical products to combat these and other illnesses. Pharmaxis has received approval to market asthma treatment Aridol in select regions. The company has research and development programs for additional disease targets such as cystic fibrosis, chronic obstructive pulmonary disease, bronchiectasis, and pulmonary fibrosis. Pharmaxis acquired respiratory therapeutics developer TOPIGEN Pharmaceuticals in 2010, adding to Pharmaxis' roster of potential treatments for respiratory disorders including asthma and COPD.

Shanghai Pharmaceutical Group, or SPGC, knows that Big Pharma is big business. One of China's largest pharmaceutical companies, SPGC makes over-the-counter (OTC) medicines, prescription drugs, active pharmaceutical ingredients (APIs), biopharmaceuticals, and traditional Chinese medicine. The vertically-integrated company distributes its wares and owns more than 1,000 retail locations. SPGC sells drugs in 30 countries from five foreign offices. Its R&D facility, Central Research Institute, operates 10 centers across China. In 1996 many small producers, including Sine, Dragon & Tiger, and Pioneer, merged to form SPGC.

Novogen Limited company was founded in 1994 and is headquartered in North Ryde, Australia. Novogen Limited is engaged in pharmaceutical research and development, and marketing of consumer healthcare products. In February, 2009, the Company announced that it focuses its activities on its oncology program. The Company operates subsidiary companies in 3 geographical areas: Australia, North America and Europe. The subsidiaries are involved in the selling and marketing of Novogen's consumer healthcare products. The Company’s product range includes Phenoxodiol, Triphendiol, NV-128, and GLYC-101. The Company’s subsidiaries include Novogen Laboratories Pty Ltd, Norvogen Pty Ltd, Glycotex, Inc. and Novogen BV.

Inviting Real Estate Agents, Job Placements Agents, Educational Institutes, Software Service Providers, Real Estate Builders, Marriage Bureaus, Travel Agents, Restaurant Owners, Health & Fitness Centers and other Local Businesses to Post a FREE Classified Advertisement on Cootera.com Classifieds Website.